Core Insights - On November 10, Dajia Weikang's stock rose by 1.70%, with a trading volume of 58.99 million yuan [1] - The company reported a financing buy-in of 10.40 million yuan and a net financing buy-in of 6.02 million yuan on the same day [1] - As of November 10, the total financing and securities lending balance for Dajia Weikang was 70.35 million yuan, indicating a high level of financing activity [1] Financing Summary - On November 10, Dajia Weikang had a financing buy-in of 10.40 million yuan, with a current financing balance of 70.35 million yuan, accounting for 2.73% of its market capitalization [1] - The financing balance is above the 50th percentile level over the past year, indicating a relatively high position [1] Securities Lending Summary - On November 10, there were no shares repaid or sold in securities lending, with a remaining quantity of 100 shares and a securities lending balance of 1,254 yuan, which is above the 80th percentile level over the past year [1] Company Performance - As of October 31, Dajia Weikang had 15,900 shareholders, a decrease of 2.91% from the previous period, with an average of 8,659 circulating shares per shareholder, an increase of 3.00% [2] - For the period from January to September 2025, Dajia Weikang achieved operating revenue of 4.13 billion yuan, a year-on-year increase of 3.69%, while the net profit attributable to shareholders decreased by 86.02% to 5.10 million yuan [2] Dividend Information - Since its A-share listing, Dajia Weikang has distributed a total of 38.07 million yuan in dividends, with 31.05 million yuan distributed over the past three years [3] - Notably, as of September 30, 2025, the fund "Noan Multi-Strategy Mixed A" (320016) has exited the list of the top ten circulating shareholders [3]

Core Insights - On November 6, Dajia Weikang's stock fell by 0.57%, with a trading volume of 40.65 million yuan [1] - As of November 6, the company had a total margin balance of 63.65 million yuan, with a net margin purchase of 1.30 million yuan on that day [1][2] - For the period from January to September 2025, Dajia Weikang reported a revenue of 4.13 billion yuan, a year-on-year increase of 3.69%, while net profit decreased by 86.02% to 5.10 million yuan [2] Financing and Margin Trading - On November 6, Dajia Weikang had a financing buy amount of 3.66 million yuan and a financing repayment of 2.36 million yuan, resulting in a net financing purchase of 1.30 million yuan [1] - The current financing balance of 63.65 million yuan accounts for 2.52% of the circulating market value, which is below the 40th percentile level over the past year, indicating a low position [1] - The company had no short selling on November 6, with a short selling balance of 1,229 yuan, which is above the 80th percentile level over the past year, indicating a high position [1] Shareholder and Dividend Information - As of October 31, the number of Dajia Weikang shareholders was 15,900, a decrease of 2.91% from the previous period, while the average circulating shares per person increased by 3.00% to 8,659 shares [2] - Since its A-share listing, Dajia Weikang has distributed a total of 38.07 million yuan in dividends, with 31.05 million yuan distributed in the last three years [3] - As of September 30, 2025, the top ten circulating shareholders of Dajia Weikang saw the exit of the Noan Multi-Strategy Mixed A fund from the list [3]

Core Viewpoint - Dajia Weikang (301126) responded to investor inquiries on November 6, indicating that the number of shareholders as of October 31, 2025, can be found in previously disclosed information [1] Summary by Categories - Company Information - Dajia Weikang has provided information regarding its shareholder count as of a future date, October 31, 2025 [1]

Core Viewpoint - The company, Dajiahui Kang, has provided information regarding the distribution of its subsidiaries' pharmacies in Hainan province, specifically in cities such as Haikou, Wenchang, Qionghai, and Ding'an [1] Company Summary - Dajiahui Kang operates two main subsidiaries: Hainan Dajiahui Kang Pharmacy Chain Co., Ltd. and Hainan Dajiahui Kang Hongchuntang Pharmacy Chain Co., Ltd. [1] - The pharmacies are primarily located in Haikou, Wenchang, Qionghai, and Ding'an, indicating a focused regional presence in Hainan [1]

Core Points - The company announced that from September 1, 2025, to November 5, 2025, a shareholder holding more than 5%, Director Zhong Xuesong, will reduce his holdings by a total of 1,000,800 shares, accounting for 0.49% of the company's total share capital [1] - Following this reduction, Zhong's shareholding will decrease from 19,288,400 shares to 18,287,600 shares, with his ownership percentage dropping from 9.39% to 8.90% [1] - This reduction in holdings is part of a previously announced plan to reduce up to 3,500,000 shares, which represents 1.70% of the total share capital, and the plan has not yet been fully executed [1]

Group 1 - The company, Dajia Weikang (301126), reported that as of October 31, 2025, the number of shareholders is 15,923 [1]

Core Viewpoint - Hunan Dajia Weikang Pharmaceutical Co., Ltd. is preparing for an IPO in Hong Kong, aiming to raise funds for expanding its retail network, upgrading logistics, enhancing marketing, and supplementing working capital [1] Group 1: Company Overview - Dajia Weikang is a comprehensive pharmaceutical service provider focused on offering a full range of health services, including the distribution and retail of pharmaceuticals and medical devices [1] - The company operates a distribution network and chain pharmacies across Hunan Province and other regions, providing products and professional services such as medication consultation and health management [1] - Dajia Weikang has established long-term partnerships with well-known domestic and international pharmaceutical manufacturers, ensuring timely and safe drug supply through integrated supply chain resources and digital management systems [1] Group 2: IPO Details - The IPO is sponsored by CITIC Construction Investment International and Huatai Financial Holdings (Hong Kong) [1] - The funds raised from the IPO will be allocated to the following purposes: expanding and optimizing the pharmaceutical retail network, upgrading logistics centers and supply chain management systems, enhancing marketing and brand building, and supplementing working capital for general corporate purposes [1]

Core Viewpoint - Dajia Weikang (301126) announced the resignation of its Vice President, Li Yulan, due to personal reasons, effective immediately, and she will no longer hold any position within the company [1] Group 1 - The company’s board of directors received the resignation report from Li Yulan [1] - Li Yulan's resignation is attributed to personal reasons [1] - Following her resignation, Li Yulan will not serve in any capacity within the company [1]

Company Overview - Dajia Weikang (SZ 301126) announced the resignation of Deputy General Manager Li Yulan due to personal reasons, effective immediately, with her term originally set from October 17, 2023, to October 9, 2026 [1] - Following her resignation, Li Yulan will no longer hold any position within the company [1] Financial Performance - For the first half of 2025, Dajia Weikang's revenue composition is as follows: retail accounted for 51.84%, wholesale for 44.29%, industrial revenue for 2.98%, other income for 0.7%, and hospital revenue for 0.19% [1] - As of the report date, Dajia Weikang's market capitalization stands at 2.5 billion yuan [1]

证券代码：301126 证券简称：达嘉维康 公告编号：2025-070 湖南达嘉维康医药产业股份有限公司 关于高级管理人员离职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025 年 10 月 31 日 2 1 展做出的贡献表示衷心感谢！ 特此公告。 湖南达嘉维康医药产业股份有限公司董事会 湖南达嘉维康医药产业股份有限公司（以下简称"公司"）董事会于近日收 到公司副总经理李玉兰女士的离职报告，李玉兰女士因个人原因申请辞去公司副 总经理职务，其原定任期为 2023 年 10 月 17 日至 2026 年 10 月 9 日，根据《中华 人民共和国公司法》（以下简称《公司法》）《公司章程》《董事、高级管理人 员离职管理制度》的规定，李玉兰女士的离职报告自送达董事会之日起生效。辞 职后，李玉兰女士不再担任公司任何职务。 截至本公告披露日，李玉兰女士直接持有公司股份 165,000 股，通过长沙同展 咨询企业合伙企业（有限合伙）间接持有公司股份 100,000 股，合计占公司总股本 比例为 0.13%，其配偶及其他关联人未持有公司股份。李玉兰女士离职后将严格 ...